1. E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama:
Synthesis and biological evaluation of molecular probes based on the
9-methylstreptimidone derivative DTCM-glutarimide. Bioorganic & Medicinal
Chemistry Letters 22: 164-167, 2012.
2. T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa and H. Kataoka:
Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule
inhibitor of nuclear factor-κB, on glioblastoma. Neuro-Oncology 14: 19-28, 2012.
3. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa
and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. Chem.
Pharm. Bull. 60: 137-143, 2012.
4. R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I.
Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells
and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology 153: 621-630, 2012.
5. M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K.
Umezawa: Involvement of DNA binding domain in the cellular stability and importin
affinity of NF-κB component RelB. Org. Biomol. Chem. 10: 3053-3059, 2012.
6. T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N.
Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and S. Todo: A novel
NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonicinjury in mice. Journal of Crohn’s and Colotis 6: 215-225, 2012.
7. T. Yasukagawa, Y. Niwa, S. Simizu and K. Umezawa: Suppression of cellularinvasion by glybenclamide through inhibited secretion of platelet-derived growth factor
in ovarian clear cell carcinoma ES-2 cells. FEBS Lett. 586:1504–1509, 2012.
8. 梅澤一夫：細胞内シグナル伝達分子と創薬。新しい薬学事典 pp110-113,朝倉書店 2012.6.25
9. N. Noma, S. Simizu, Y. Kambayashi, Y. Kabe, M. Suematsu, and K. Umezawa:
Involvement of NF-κB-mediated expression of galectin-3-binding protein in tumor
necrosis factor-α-induced breast cancer cell adhesion. Oncology Reports 27: 2080-2084,

1

2012.
10. Y. Niwa, C. Matsui, N. Sukumwang, H. Iinuma, Y. Ikeda, T. Koyano, T.
Kovitayakorn, S. Simizu and K. Umezawa: Inhibition of lysenin-induced hemolysis by
all-E-lutein derived from the plant Dalbergia latifolia. Planta Medica 78: 957-961,
2012.
11. M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K.
Miyazono: TGF-β-induced epithelial-mesenchymal transition of A549 lungadenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW
264.7 macrophage cells. J. Biochem. 151: 205-216, 2012.
12. R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R.
Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki,
and S. Todo: The immunomodulatory effect of nuclear factor-κB inhibition by
dehydroxymethylepoxyquinomicin in combination with donor-specific bloodtransfusion. Transplantation 93: 777-786, 2012.
13. N. Lampiasi, A. Azzolina1, K Umezawa, G. Montalto, J. A. McCubrey and M.
Cervello: The novel NF-κB inhibitor DHMEQ synergizes with Celecoxib to exert
antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer
Lett. 322: 35-44, 2012.
14. K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa,
M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. Tojo and N. Gotoh: ErbB receptor
tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast
cancer. Proc. Natl. Acad. Sci. USA 109: 6584-6589, 2012.
15. K. Shimizu, S. Konno, M. Ozaki, K. Umezawa, K. Yamashita, S. Todo and M.
Nishimura: Dehydroxymethylepoxyquinomicin (DHMEQ), a novel NF-kappaB
inhibitor, inhibits allergic inflammation and airway remodelling in murine models ofasthma. Clin. Exp. Allergy 42: 1273–1281, 2012.
16. A. Kaneda, S. K. Gantsev and K. Umezawa: Inhibition of cellular invasion andinduction of anoikis in mouse melanoma cells by an anti-inflammatory agent
DTCM-glutarimide. Creative Surgery and Oncology 2012: 4-9, 2012.

2

17. M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa:
Structure-activity relationship of 9-methylstreptimidone that induces selective apoptosis
in adult T-cell leukemia cells. Oncology Res. 20: 7-14, 2012.
18. M. S. Brassesco, J. A. Pezuk, A. G. Morales, J. C. de Oliveira, E. T. Valera, G. N.
da Silva, H. F. de Oliveira, C. A. Scrideli, K. Umezawa, L. G. Tone: Cytostatic in vitro
effects of DTCM-glutarimide on bladder carcinoma cells. Asian Pacific Journal ofCancer Prevention 13: 1957-1962, 2012.
19. M. Nakayama, Y. Niki, T. Kawasaki, Y. Takeda, K. Horiuchi, A. Sasaki, Y. Okada,
K. Umezawa, H. Ikegami, Y. Toyama and T. Miyamoto: Enhanced susceptibility tolipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alphatransgenic mice through induction of tumor necrosis factor alpha. Arthritis Research &Therapy 14:R120 http://arthritis-research.com/content/14/3/R120, 2012.
20. R. Kobayashi, K. Hanaya, M. Shoji, K. Umezawa and T. Sugai: A chemo-enzymatic
expeditious
routetoracemic
dihexanoyl(2R*,3R*,4R*)-dehydroxymethylepoxyquinomycin (DHMEQ), the precursor forlipase-catalyzed synthesis of the potent NF-κB Inhibitor, (2S,3S,4S)-DHMEQ.
Chemical and Pharmaceutical Bulletin 60: 1220-1223, 2012.
21. C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S.
Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces theco-expression of IL-6 and PAI-1 via NFκB pathway on advanced-stage epithelial
ovarian cancer. Oncogene 31: 4139-4149, 2012.
22. A. M. Castro-Gamero, K. S. Borgesa, V. da Silva Silveira, R. C. P. Lira, R. de Paula
G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of
nuclear factor-κB by dehydroxymethylepoxyquinomicin induces schedule-dependent
chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis inosteosarcoma cells. Anti-Cancer Drugs 2012: 638-650, 2012.
23. F. C.P. Valera, K. Umezawa, M. S. Brassesco, A. M. C. Gamero, R. G. P. Queiro, C.
A. Scrideli, L. G. Tone, W. T. Anselmo-Lima: Suppression of inflammatory cytokine
secretion by an NF-κB inhibitor in nasal polyps fibroblasts. Cellular Physiology and3

Biochemistry 30: 13-22, 2012.
24. N. Kozakai, E. Kikuchi, M. Hasegawa, E. Suzuki, H. Ide, A. Miyajima, Y.
Horiguchi, J. Nakashima, K. Umezawa, N. Shigematsu and M. Oya: Enhancement ofradiosensitivity by a unique novel NF-κB inhibitor, DHMEQ, in prostate cancer. British
J. Cancer 107: 652-657, 2012.
25. Y. Niwa, T. Suzuki, N. Dohmae, K. Umezawa and S. Simizu: Determination ofcathepsin V activity and intracellular trafficking by N-glycosylation. FEBS Lett. 586:
3601–3607, 2012.
26. M. Nishimura, T. Nii, G. Trimova, S. Miura, K. Umezawa, A. Ushiyama, T.
Kubota: The NF-κB specific inhibitor DHMEQ prevents thrombosis formation in amouse model of antiphospholipid syndrome. J. Nephropathology 2 (2):114-121, 2013.
27. T. Shimo, Y. Adachi, S. Yamanouchi, S. Tsuji, T. Kimata, K. Umezawa, M.
Okigaki, J. Takaya, S. Ikehara, K. Kaneko: A novel NF- kappaB inhibitor DHMEQ
ameliorates puromycin aminonucleoside induced nephrosis in mice. Am. J. Nephrol. 37:
302–309, 2013.
28. A. Ogasawara, S. Simizu, A. Ito, T. Kawai, Y. Saisho, I. Takei and K. Umezawa:
Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (-)-DHMEQ via
activation of Nrf2-ARE pathway. Biochem. Biophys. Chem. Commun. 433: 181–187,
2013.
29. K. Sidthipong, S. Todo, I. Takei, I. Kojima and K. Umezawa: Screening of new
bioactive metabolites for diabetes therapy (Review). Intern. Emerg. Med. 8 (Suppl 1):
S57-S59, 2013.
30. S. Shibasaki, K. Yamashita, R. Goto, K. Wakayama, Y. Tsunetoshi, M. Zaitsu, R.
Igarashi, S. Haga, M. Ozaki, K. Umezawa and S. Todo: Immunosuppressive effects of
DTCM-G, a novel inhibitor of the mTOR downstream signaling pathway.
Transplantation 95: 542-550, 2013.
31. K. Suzuki, K. Aiura, S. Matsuda, O. Itano, O. Takeuchi, K. Umezawa, and Y.
Kitagawa: Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a4

mouse model of liver metastasis of pancreatic cancer. Clinical & Experimental
Metastasis 30:381-392, 2013.
32. Y. Arai, H. Iinuma, Y. Ikeda, M. Igarashi, K. Hatano, N. Kinoshita, T. Ukaji, S.
Simizu and K. Umezawa: Migracins A and B, new inhibitors of cancer cell migration,
produced by Streptomyces sp. J. Antibiot. 66: 225–230, 2013.
33. M. S. Brassesco, J. A. Pezuk, J. C. de Oliveira, E. T. Valera, H. F. de Oliveira, C. A.
Scrideli, K. Umezawa and L. G. Tone: Activator Protein-1 Inhibition by
3-[(dodecylthiocarbonyl)methyl]-glutamaride impairs invasion and radiosensitizes
osteosarcoma cells in vitro. Cancer Biotherapy and Radiopharmaceuticals 28: 351-358,
2013.
34. M. S. Brassesco, G. Roberto, A. Morales, J. de Oliveira, L. E. Delsin, J. A. Pezuk, E.
T. Valera, C. G. Carlotti Jr., E. M. Rego, H. F. de Oliveira, C. A. Scrideli, K. Umezawa
and L. G. Tone: Inhibition of NF-κB by dehydroxymethylepoxyquinomicin suppresses
invasion and synergistically potentiates Temozolomide and γ-radiation cytotoxicity inglioblastoma cells. Chemotherapy Research and Practice, Volume 2013 Article ID
593020 (16 pages), 2013.
35. K. Umezawa: Peritoneal NF-κB as a Possible molecular target for suppression ofvarious cancers and inflammation. (Review) Forum of Immunopathological Diseases
and Therapeutics 4: 63-77, 2013.
36. S. Nakajima, H. Kato, L. Gu, S. Takahashi, H. Johno, K. Umezawa and M.
Kitamura: Pleiotropic potential of dehydroxymethylepoxyquinomicin for NF-κB
suppression via reactive oxygen species and unfolded protein response. J. Immunol.
190: 6559-6569, 2013.
37. M. Kassan, S. K. Choi, M. Galán, A. Bishop, K. Umezawa, M. Trebak, K.
Matrougui: NFκB impairs vascular function through PARP-1, SP-1 andCOX2-dependent mechanisms in type 2 diabetes. Diabetes 62: 2078-2087, 2013.
38. T. Ohsugi, T. Ishida, T. Shimasaki, S. Okada and K. Umezawa: p53 dysfunction
precedes the activation of nuclear factor-κB during disease progression in mice5

expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. Carcinogenesis 34:
2129-2136, 2013.
39. M. Kuroda, S. Funasaki, T. Saitoh, Y. Sasazawa, S. Nishiyama, K. Umezawa and S.
Simizu: Determination of topological structure of ARL6ip1 in cells: Identification of theessential binding region of ARL6ip1 for conophylline. FEBS Letters 587: 3656-3660,
2013.
40. T. Togano, M. Nakashima, M. Watanabe, K. Umezawa, T. Watanabe, M.
Higashihara and R. Horie: Synergistic effect of 5-azacytidine and NF-kappa B inhibitor
DHMEQ on apoptosis induction in myeloid leukemia cells. Oncology Res. 20: 571-577,
2013.
41. N. Sukumwang and K. Umezawa: Earthworm-derived pore-forming toxin Lysenin
and screening of its inhibitors. Toxins 5: 1392-1401, 2013.
42. T. Ukaji, S. Gantsev and K. Umezawa: Inhibition of Cancer cell invasion andmetastasis by NF-kappa B inhibitors. (Review) Creative Surgery and Oncology 2013(3): 6-12, 2013.
43. S. K. Gantsev, K. Umezawa, D. V. Islamgulov, E. K. Husnutdinova, R. S.
Ishmuratova, V. Y. Frolova, S. R. Kzyrgalin: The role of inflammatory chemokines inlymphoid neoorganogenesis in breast cancer. Biomedicine & Pharmacotherapy 67:
363-366, 2013.
44. D. Kuraya, M. Watanabe, Y. Koshizuka, M. Ogura, T. Yoshida, Y. Asahi, H.
Kamachi, T. Nakamura, H. Harashima, M. Ozaki, K. Umezawa, M. Matsushita, K.
Yamashita, and S. Todo: Efficacy of DHMEQ, a NF-κB Inhibitor, in islet
transplantation: I. HMGB1 suppression by DHMEQ prevents early islet graft damage.
Transplantation 96: 445-453, 2013.
45. H. Kono, K. Nakagawa, S. Morita, K. Shinoda, R. Mizuno, E. Kikuchi, A. Miyajima,
K. Umezawa and M. Oya: Effect of a novel nuclear factor kappaB activation inhibitor
on renal ischemia reperfusion injury. Transplantation 96: 863-870, 2013.
46. S. Shimogaki, S. Ito, S. Komatsu, R. Koike, N. Miyasaka, K. Umezawa and T.

6

Kubota: Inhibition of the NF-κB pathway as a candidate therapeutic strategy forcryopyrin-associated periodic syndrome. Mod. Rhumatol. 24: 517-524. doi:
10.3109/14397595.2013.844298. Epub 2013 Nov 4.
47. M. Watanabe, K. Yamashita, H. Kamachi, D. Kuraya, Y. Koshizuka, S. Shibasaki,
Y. Asahi, H. Ono, S. Emoto, M. Ogura, T. Yoshida, M. Ozaki, K. Umezawa, M.
Matsushita and S. Todo: Efficacy of DHMEQ, a NF-κB inhibitor, in islet
transplantation: II. Induction DHMEQ treatment ameliorates subsequent alloimmune
responses and permits long-term islet allograft acceptance. Transplantation 96: 454-462,
2013.
48. 梅澤一夫：糖尿病治療に有用なシグナル伝達阻害剤の探索と分子デザイン。
Screening and molecular design of signal transduction inhibitors for diabetes therapy.
日本糖尿病眼学会誌 18: 13-19, 2013.
49. N. Kubo, R. Saito, K. Hamano, M. Nagasawa, F. Aoki, I. Takei, K. Umezawa, H.
Kuwano and I. Kojima: Conophylline suppresses hepatic stellate cells and attenuates
thioacetamide-induced liver fibrosis in rats. Liver International 2013,
DOI: 10.1111/liv.12328.
50. T. Ukaji, Y. Sasazawa, K. Umezawa and S. Simizu: Involvement of conserved
tryptophan residues for secretion of TIMP-2. Oncology Letters 7: 631-634, 2014.
51. T. Togano, M. Watanabe, K. Itoh, K. Umezawa, N. Masuda, M. Higashihara and R.
Horie: Activation of Akt involves resistance to NF-κB inhibition and abrogation of both
triggers synergistic apoptosis in lung adenocarcinoma cells. Lung Cancer 83: 139-145,
2014.
52. M. Watanabe, K. Umezawa, M. Higashihara and R. Horie: Combined inhibition of
NF-κB and Bcl-2 triggers synergistic reduction of viability and induces apoptosis inmelanoma cells. Oncology Res. 21: 173-180, 2014.
53. Y. Goto, Y. Niwa, T. Suzuki, N. Dohmae, K. Umezawa and S. Simizu:
C-mannosylation of human hyaluronidase 1: Possible roles for secretion and enzymatic
activity. International J. Oncology 45: 344-350, 2014.

7

54. M. El-Salhy, K. Umezawa, O.-H. Gilja, J. G. Hatlebakk, D. Gundersen and T.
Hausken: Amelioration of severe TNBS induced colitis by novel AP-1 and NF-κB
inhibitors in rats. The Scientific World Volume 2014 Article ID 813804 (8 pages)
55. M. Celegato, C. Borghese, K. Umezawa, N. Casagrande, A. Colombatti, A. Carbone,and D. Aldinucci: The NF-κB inhibitor DHMEQ decreases survival factors, overcomesthe protective activity of microenvironment and synergizes with chemotherapy agents inclassical Hodgkin lymphoma. Cancer Letters 349: 26-34, 2014.
56. H. Nishio, T. Yaguchi, J. Sugiyama, H. Sumimoto, K. Umezawa, T. Iwata, N.
Susumu, T.Fujii, N. Kawamura, A. Kobayashi, J-H Park, D. Aoki, Y. Kawakami:
Immunosuppression through constitutively activated NF-κB signaling in human ovariancancer and its reversal by a NF-κB inhibitor. British J. Cancer 110: 2965-2974, 2014.
57. M. Sato, K. Nakanishi, S. Haga, M. Fujiyoshi, M. Baba, K. Mino, Yimin, H. Niwa,
H. Yokoo, K. Umezawa, Y. Ohmiya, T. Kamiyama, S. Todo, A. Taketomi and M.
Ozaki: Anoikis induction and inhibition of peritoneal metastasis of pancreatic cancer
cells by a nuclear factor-kappa B inhibitor, (-)-DHMEQ. Oncology Res. 21: 333-343,
2014..
58. T. Ukaji and K. Umezawa: Novel approaches to target NF-κB and other signaling
pathways in cancer stem cells. Advances in Biological Regulation 56: 108-115, 2014.
59. N. Koide, Y. Kondo, E. Odkhuu, J. Ulziisaikhan, T. Ukaji, T. Yokochi and K.
Umezawa: Inhibition of receptor activator of nuclear factor-κB ligand (RANKL) or
lipopolysaccharide-induced osteoclast formation by conophylline (CNP) throughdownregulation of CREB. Immunology Letters 161: 31-37, 2014.
60. C. Matsui, Y. Ikeda, H. Iinuma, N. Kushida, T. Kunisada, S. Simizu and K.
Umezawa: Isolation of a novel paxilline analog pyrapaxilline from fungus that inhibits
LPS-induced NO production. J. Antibiotics 67: 787-790, 2014.
61. S. Haga, T. Ozawa, Y. Yamada, N. Morita, I. Nagashima, H. Inoue, Y. Inaba, N.
Noda, R. Abe, K. Umezawa and M. Ozaki: p62/SQSTM1 plays a protective role inoxidative injury of steatotic liver in a mouse hepatectomy model. Antioxidants andRedox Signaling 18: 2515-2530, 2014.

8

62. N. Lampiasi, K. Umezawa, G. Montalto, M. Cervello: Poly (ADP-Ribose)polymerase inhibition synergizes with the NF-κB inhibitor DHMEQ to killhepatocellular carcinoma cells. BBA - Molecular Cell Research 1843: 2662-2673, 2014.
63. T. Miyagi, B. Shiotani, R. Miyoshi, T. Yamamoto, T. Oka, K. Umezawa, T. Ochiya,
M. Takano and H. Tahara: DSE-FRET: A new anti-cancer drug screening assay for
DNA binding proteins. Cancer Science 105: 870-874, 2014.
64. W. Seubwai, R. Kraiklang, K. Vaeteewoottacharn, K. Umezawa, S. Okada, S.
Wongkham: Aberrant expression of NF-κB in liver fluke associatedcholangiocarcinoma: implications for targeted therapy. PLOS ONE 9 (8): e106056,
2014.
65. M. Kamoshita, Y. Ozawa, S. Kubota, S. Miyake, C. Tsuda, N. Nagai, K. Yuki, S.
Shimmura, K. Umezawa and K. Tsubota. AMPK-NF-κB axis in the photoreceptor
disorder during retinal inflammation. PLoS One 9 (7): e103013, 2014.
66. S. Heavey, P. Godwin, A.-M. Baird, M. P. Barr, K. Umezawa, S. Cuffe, S. P. Finn,
K. J. O’Byrne and K. Gately: Strategic targeting of the PI3K-NFκB axis in
cisplatin-resistant NSCLC. Cancer Biology & Therapy 15: 1367-1377, 2014..
67. S. Inokawa, T. Watanabe, H. Keino, Y. Sato, A. Hirakata, A. A. Okada, K. Fukuda,
A. Fukushima and K. Umezawa: Dehydroxymethylepoxyquinomicin, a novel nuclear
factor–κB inhibitor, reduces chemokines and adhesion molecule expression induced by
IL-1β in human corneal fibroblasts. Graefes Arch. Clin. Exp. Ophthalmol. 253: 557-563,
2015
68. M. Kuboki, A. Ito, S. Simizu and K. Umezawa: Activation of apoptosis by
caspase-3-dependent specific RelB cleavage in anticancer agent-treated cancer cells:
Involvement of positive feedback mechanism. Biochem. Biophys. Res. Commun. 456:
810–814, 2015.
69. N. Koide, A. Kaneda, T. Yokochi and K. Umezawa: Inhibition of RANKL- and
LPS-induced osteoclast differentiations by novel NF-κB inhibitor DTCM-glutarimide.
International Immunopharmacology 25: 162-168, 2015.

9

70. K. Horie, J. Ma and K. Umezawa: Inhibition of canonical NF-κB nuclear
localization by (-)-DHMEQ via impairment of DNA binding. Oncology Res. 22:
105-115, 2015.
71. N. Noma, M. Asagiri, M. Takeiri, S. Ohmae, K. Takemoto, K. Iwaisako, S. Simizu
and K. Umezawa: Inhibition of MMP-2-mediated mast cell invasion by NF-κB inhibitor
DHMEQ in mast cells. International Achieves of Allergy and Immunology 166: 84-90,
2015.
72. J. C. Mbongue, D. Nicholas, K. Zhang, B. N. Hamilton, M. Larios, G. Zhang, K.
Umezawa, A. Firek and W. H. R. Langridge: Induction of indoleamine 2, 3 dioxygenasein human dendritic cells by a cholera toxin B subunit - Proinsulin vaccine. PLOS ONE
DOI: 10.1371/journal.pone.0118562, 2015.
73. Y. Sasazawa, N. Sato, K. Umezawa and S. Simizu: Conophylline protects cells incellular models of neurodegenerative diseases by inducing mTOR-independent
autophagy. J. Biol. Chem. 290: 6168-6178, 2015.
74. Y. Ito, E. Kikuchi, N. Tanaka, T. Kosaki, E. Suzuki, R. Mizuno, T. Shinojima, A.
Miyajima, K. Umezawa and M. Oya: Down-regulation of NF kappa B activation is aneffective therapeutic modality in acquired platinum-resistant bladder cancer. BMC
Cancer 2015 15:324. DOI: 10.1186/s12885-015-1315-9. Open access.
75. S. Yamanouchi, Y. Adachi, T. Shimo, K. Umezawa, M. Okigaki, S. Tsuji, M Li, J.
Takaya, T. Kuge, S. Ikehara, K. Kaneko: A nuclear factor-κB inhibitor,
dehydroxymethylepoxyquinomicin, ameliorates GVHD in allogeneic bone marrowtransplantation. Immunobiology 220: 1059-1066, 2015.
76. M. Zaitsu, K. Yamashita, S. Shibasaki, Y. Tsunetoshi, M. Fukai, M. Ogura, T.
Yoshida, R. Igarashi, N. Kobayashi, K. Umezawa and S. Todo:
3-[(dodecylthiocarbonyl)methyl]-glutarimide attenuates graft arterial disease by
suppressing alloimmune responses and vascular smooth muscle cell proliferation.
Transplantation 99: 948-956, 2015. doi: 10.1097/TP.576.
77. T. Toda, M. Watanabe, J. Kawato, M. Higashihara, T. Kunisada, K. Umezawa and10

R. Horie: Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive
anaplastic large cell lymphoma and Hodgkin lymphoma cell lines. British J.
Haematology 170: 837-846, 2015.
78.T. F. S. Ali, K. Iwamura, H. I. Ciftci, R. Koga, M. Matsumoto, Y. Oba, H. Kurosaki,
M. Fujita, Y. Okamoto, K. Umezawa, M. Nakao, T. Hide, K. Makino, J. Kuratsu, M.
Abdel-Aiziz, G. El-Din, A. A. Abuo-Rahma, E. A. M. Beshr and M. Otsuka: Novel
metal chelating molecules with anticancer activity. Striking effect of the imidazole
substitution of the histidine–pyridine– histidine system. Bioorg. Med. Chem. 23:
5476-5482, 2015.
79. T. Ukaji, Y. Lin, K. Banno, S. Okada and K. Umezawa: Inhibition of
IGF-1-mediated cellular migration and invasion by migracin A in ovarian clear cell
carcinoma cells. PLOS One 10(9): e0137663, 2015 DOI:10.1371/journal.pone.0137663.
80. G. Malaponte, S. S. Signorelli, V. Bevelacqua, J. Polesel, M. Taborelli, C. Guarneri,
C. Fenga, K. Umezawa, and M. Libra: Increased levels of NF-κB-dependent markers incancer-associated deep venous thrombosis. PLOS One. 2015; 10(7): e0132496.
81. L. Wang, Y. Lin, K. Sidthipong, J. Tang, M. Li, T. Koyano, T. Kowithayakorn, K.
Sumiyoshi, T. Ukaji, and K. Umezawa: Inhibition of NF-κB and cellular invasion by
novel flavonoid desmal in ovarian carcinoma cells. Heterocycles 92: 353-360, 2016.
82. W. Seubwai, K. Vaeteewoottacharn, R. Kraiklang, K. Umezawa, S. Okada and S.
Wongkham: Inhibition of NF-κB activity enhances sensitivity to anticancer drugs incholangiocarcinoma cells. Oncology Research 23: 21-28, 2016.
83. M. El-Salhy and K. Umezawa: Treatment with novel AP-1 and NF-κB inhibitors
restores the colonic endocrine cells to normal levels in rats with DSS-induced colitis.
International J. Molecular Medicine DOI: 10.3892/ijmm.2016.2481.
84. M. El-Salhy and K. Umezawa: Anti-inflammatory effects of novel AP-1 and NF-κB
inhibitors in dextran-sulfate-sodium-induced colitis in rats. International J. Mol. Med.
DOI: 10.3892/ijmm.2016.2560.

11

85. T. Okamoto, Y. Ozawa, M. Kamoshita, H. Osada, E. Toda, T. Kurihara, N. Nagai,
K. Umezawa and K. Tsubota: The neuroprotective effect of rapamycin as a modulatorof the mTOR-NF-κB axis during retinal Inflammation. PLOS One published 15 Jan
2016 10.1371/journal.pone.0146517.
86. M. Hirasawa, K. Takubo, H. Osada, S. Miyake, E. Toda, M. Endo, K. Umezawa, K.
Tsubota, Y. Oike and Y. Ozawa: Angiopoietin-like protein 2 is a multistep regulator of
inflammatory neovascularization in a murine model of age-related macular degeneration.
J. Biol. Chem. 291: 7373-7385, 2016. doi:10.1074/jbc.M115.710186.
87. M. Murahashi, S. Simizu, M. Morioka and K. Umezawa: Identification of poly(rC)binding protein 2 (PCBP2) as a target protein of immunosuppressive agent
15-deoxyspergualin. Biochem. Biophys. Res. Commun. 476: 445-449, 2016.
88. M. El-Salhy and K. Umezawa: Effects of AP-1 and NF-kappa B inhibitors oncolonic endocrine cells in rats with TNBS-induced colitis. Molecular Medicine Reports
14: 1515-1522, 2016.
89. M. Morioka, K. Kato, and K. Umezawa: Design and synthesis of
15-deoxyspergualin-biotin conjugates as novel binding probes for target protein
screening. J. Antibiotics 69: 574-578, 2016.
90. S. K. Gantsev, K. Umezawa, V. S. Vagapova, K. S. Gantsev, S. V. Solomenny, S. R.
Kzyrgalin, R. S. Yamidanov, E. A. Gantseva: Calcification of peritoneum andperitoneal fluid perfusion malfunction in carcinomatosis of serous membranes ofperitoneal cavity. Journal of Cancer Research & Therapy 4: 38-41, 2016.
91. M. El-Salhy, T. Mazzawi, K. Umezawa and O. H. Jilja: Enteroendocrine cells, stem
cells and differentiation progenitors in rats with TNBS-induced colitis. International J.
Mol. Med. DOI: 10.3892/ijmm.2016.2787.
92 S. Katsuyama, K. Sugino, Y. Sasazawa, Y. Nakano, H. Aono, K. Morishita, M.
Kawatani, K. Umezawa, H. Osada and S. Simizu: Identification of a novel compoundthat inhibits osteoclastogenesis by suppressing nucleoside transporters. FEBS Letters
590: 1152–1162, 2016.

12

93. J. T. Burgess, E. Bolderson, M. N. Adams, A.-M. Baird, S.-D. Zhang, K. J. Gately,
K. Umezawa, K. J. O’Byrne, and D. J. Richard: Activation and cleavage of SASH1 by
Caspase-3 mediates an apoptotic response. Cell Death Disease 7: e7460, 2016.
94. M. Kawaguchi, K. Yamamoto, A. Kanemaru, H. Tanaka, K. Umezawa, T.
Fukushima, H. Kataoka: Inhibition of nuclear factor-κB signaling suppresses
Spint-1-deletion-induced tumor susceptibility in the ApcMin/+ mode. Oncotarget 7(42): 68614-68622, 2016.
95. N. Ichikawa, K. Yamashita, F. Funakoshi, S. Ichihara, M. Fukai, M. Ogura, N.
Kobayashi, M. Zaitsu, Y. Yoshida, S. Shibasaki, Y. Koshizuka, Y. Tsunetoshi, M. Sato,
T. Einama, M. Ozaki, K. Umezawa, T. Suzuki and S. Todo: Novel anti-inflammatory
agent 3-[(dodecylthiocarbonyl)-methyl]-glutarimide ameliorates murine models of
inflammatory bowel disease. Inflammation Research 65: 245-260, 2016.
96. P. Sosińska, B. Maćkowiak, R. Staniszewski, K. Umezawa and A. Bręborowicz:
Inhibition of NF-κB with dehydroxyepoxiquinomicin modifies function of humanperitoneal mesothelial cells. American Journal of Translational Research 8: 5756-5765,
2016.
97. J. A. Pezuk, G. M. Roberto and K. Umezawa and M.S. Brassesco:
DTCM-glutarimide hinders growth of childhood leukemia cells but fails to improve theefficacy of commonly used chemotherapeutic agents. Current Bioactive Compounds 13:
41-46, 2016.
98. K. Sidthipong, J. Ma, W. L. Yu, Y. F. Wang, S. Kobayashi, S. Kishino , N. Koide, T.
Yokochi, K. Kato, S. Okada and K. Umezawa: Rational design, synthesis and in vitro
evaluation of novel exo-methylene butyrolactone salicyloylamide as NF-κB inhibitor.
Bioorg. Med. Chem. Lett. 27: 562-566, 2017.
99. T. Ikezoe, J. Yang, C. Nishioka, K. Umezawa and A. Yokoyama: Thrombomodulin
blocks calcineurin inhibitor-induced vascular permeability via inhibition of
Src/VE-cadherin axis. Bone Marrow Transplantation 52: 245–251, 2017.
100. T. Ukaji, Y. Lin, S. Okada and K. Umezawa: Inhibition of MMP-2-mediatedcellular invasion by NF-kB inhibitor DHMEQ in 3D culture of breast carcinoma

13

MDA-MB-231 cells: A model for early phase of metastasis. Biochem. Biophys. Res.
Commun. 485: 76-81, 2017..
101. M. El-Salhy, K. Umezawa, J. G. Hatlebakk and O. H. Gilja: Abnormal
differentiation of stem cells into enteroendocrine cells in rats with DSS-induced colitis.
Mol. Med. Reports 15: 2106-2112, 2017.
102. X. Jiang, B. Wei, Y. Lan, C. Dai, Y. Gu, J. Ma, X. Liu, K. Umezawa and Y.
Zhang: External application of NF-κB inhibitor DHMEQ suppresses development of
atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice.
Immunopharmacology and Immunotoxicology 39:3, 157-164. 2017.
103. L. Wang, M. Li, J. Tang, Y. Y. Lin, K. Sidthipong, N. Sumida, N. Kushida and K.
Umezawa: Novel p-terphenyl glycoside with a rare 2,6-dideoxy- hexopyranose moiety
from Actinomycete strain SF2911 that inhibits cancer cell migration. J. Antibiot. 70:
987-990, 2017.
104. Y. Nakade, K. Sakamoto, T. Yamauchi, Tadahisa Inoue, Y. Kobayashi, T.
Yamamoto, N. Ishii, T. Ohashi; Y. Sumida; K. Ito, H. Nakao, Y. Fukuzawa, K.
Umezawa and M. Yoneda: Conophylline inhibits non-alcoholic steatohepatitis in mice.
PLOS One 2017 Jun 8;12(6):e0178436.
105. 梅澤一夫：カナマイシン耐性機構の解明とケミカルバイオロジー。Japanese
Journal of Antibiotics 70: 351-354, 2017.
106. C-P. Simon-Gabriel, K. Foerster, M. Benkisser-Petersen, D. Bleckmann, N.
Thornton, K. Umezawa, S. Decker, C. Dierks, M. Burger, H. Veelken, R. Claus, J.
Duyster, K. Zirlik: The microenvironmental stromal cells abrogate NF-κB inhibitor
induced apoptosis in chronic lymphocytic leukemia. Hematologica November 2017 :haematol.2017.165381 Doi:10.3324/haematol.2017.165381.
107. T. Ukaji, N. Koide, Y. Lin, K. Banno, S. Gantsev and K. Umezawa: Molecular
design of sugar-free migracin analog migracinal that inhibits ovarian cancer cell
migration and invasion. Creative Surgery and Oncology 7 (4): 16-20, 2017.
DOI:10.24060/2076-3093- 2017-7-4-16-20.

14108. T. Fujii, N. Fujita, S. Suzuki, K. Watanabe, T. Tsuji, K. Ishii, T. Takaki, K.
Umezawa, T. Miyamoto, K. Horiuchi, M. Matsumoto, M. Nakamura: The unfolded
protein response mediated by PERK is casually related to the pathogenesis ofintervertebral disc degeneration. Journal of Orthopaedic Research 36: 1334-1345, 2017.
Version of Record online: 28 Nov 2017, DOI: 10.1002/jor.23787.
109. K. Umezawa, I. Kojima, S. Simizu, Y. Lin, H. Fukatsu, N. Koide, Y. Nakade andM. Yoneda: Therapeutic activity of plant-derived alkaloid conophylline on metabolic
syndrome and neurodegerative disease models (Review). Human Cell 31: 95-101, 2018.
110. Y. Lin, T. Ukaji, N. Koide and K. Umezawa: Inhibition of late and early phases ofcancer metastasis by NF-κB inhibitor DHMEQ derived from microbial bioactive
metabolite epoxyquinomicin: A review. Int. J. Mol. Sci. 2018, 19, 729;
doi:10.3390/ijms19030729
111. G. B. M. Roberto, H. H. Paiva, L. E. B. deSouza, J. A. Pezuk, G. M. Vieira, H. F.
deOliveira, K. Umezawa, L. G. Tone and M. S. Brassesco: DTCM-glutarimide delays
growth and radiosensitizes glioblastoma. Anti-cancer Agents in Medicinal Chemistry 18,
2018, DOI:10.2174/1871520618666180423105740.
112. H. Fukatsu, N. Koide, S. Tada-Oikawa, K. Izuoka, A. Ikegami, S. Ichihara, T.
Ukaji, N. Morita, Y. Naiki, T. Komatsu and K. Umezawa: NF-κB inhibitor DHMEQ
inhibits titanium dioxide nanoparticle-induced interleukin-1β production: Inhibition of
PM2.5-induced inflammation model. Molecular Medicine Reports 18: 5279-5285, 2018.
DOI:10.3892/mmr.2018.9533.
113. X. Jiang, H. He, Z. Xie, H. Wen, X. Li, Xin Li, J. Ma, K. Umezawa and Y. Zhang:
Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a
stratum corneum-removed murine model through NF-κB inhibition.
Immunopharmacology and Immunotoxicology 41: 32-39, 2019 DOI:
10.1080/08923973.2018.1510962
114. T. Tezuka, A. Ota, S. Karnan, K. Matsuura, K. Yokoo, Y. Hosokawa, D. Vigetti, A.
Passi, S. Hatano, K. Umezawa and H. Watanabe: The plant alkaloid conophylline
inhibits matrix formation of fibroblasts. J. Biol. Chem. 293: 20214 –20226, 2018.

15

115. T. Ohashi, Y. Nakade, M. Ibusuki, R Kitano, T. Yamauchi, S. Kimoto, T. Inoue, Y.
Kobayashi, N. Ishii, Y. Sumida, K. Ito, H. Nakao, K. Umezawa and M. Yoneda:
Conophylline inhibits high fat diet-induced non-alcoholic fatty liver disease in mice.
PLOS One https://doi.org/10.1371/journal.pone.0210068, 2018.
116. N. Ishii, K. Araki, T. Yokobori, K. Hagiwara, G. Dolgormaa, T. Yamanaka, T.
Handa, M. Tsukagoshi, T. Igarashi, A. Watanabe, N. Kubo, N. Harimoto, A. Masamune,
K. Umezawa, H. Kuwano and K. Shirabe: Conophylline suppresses pancreatic cancer
desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.
Cancer Science 10:334-344, 2019. DOI: 10.1111/cas.13874.
117. Y. Lin, Y. Chen, T. Ukaji, S. Okada and K. Umezawa: Isolation of ketomycin fromActinomycetes as an inhibitor of 2D and 3D cancer cell invasion. J. Antibiot. 72:
148-154, 2019.
118. Y. Ando, H. Keino, A. Kudo, A. Hitrakata, A. A. Okada and K. Umezawa:
Anti-Inflammatory effect of dehydroxymethylepoxyquinomicin, a nuclear factor–κB
inhibitor, on endotoxin-induced uveitis in rats in vivo and in vitro. Occular Immunology& Inflammation 28: 240-248, 2019, DOI: 10.1080/09273948.2019.1568502.
119. H. He, X. Gao, X. Wang, X. Li, X. Jiang, Z. Xie, K. Ma, J. Ma, K. Umezawa and
Y. Zhang: Comparison of anti-atopic dermatitis activities between DHMEQ andtacrolimus ointments in mouse model without stratum corneum. International
Immunopharmacology 71:43-51, June 2019.
https://doi.org/10.1016/j.intimp.2019.03.015
120. K. Shiraiwa, M. Mitsutake, Y. Nakazawa, T. Ogi, K. Suzuki, V. Saenko, K.
Umezawa, S. Yamashita and K. Tsukamoto: The JAK/STAT3 and NF-κB signaling
pathways regulate cancer stem cell properties in anaplastic thyroid cancer cells. Thyroid
29: 674-682, 2019 DOI: 10.1089/thy.2018.0212
121. G. A. Bonafé, J. S. dos Santos, J. V. Ziegler, K. Umezawa, M. L. Ribeiro, T.
Rocha and M. M. Ortega: Growth inhibitory effects of dipotassium glycyrrhizinate inglioblastoma cell lines by targeting microRNAs through the NF-κB signaling pathway.
Frontiers in Cellular Neuroscience Volume 13: Article 216doi:
10.3389/fncel.2019.00216.

16122. A. Breborowicz and K. Umezawa: Causes and mechanisms of peritoneal fibrosis
and possible application of NF-κB inhibitor for prevention and treatment. Journal of
Medical Science 88: 102-111, 2019 DOI: https://doi.org/10.20883/jms.352.
123. H. Fu, M. Alabdullah, J. Großmann, F. Spieler, R. Abdosh, V. Lutz, K. Kalies, K.
Knopp,K. Rieckmann, S. Koch, M. Nutsias, C. Pilowski, J. Dutzmann D. Sedding, S.
Hüttelmaier, K. Umezawa, K. Werdan and H. Loppnow: The differential statin effect on
cytokine production of monocytes or macrophages is mediated by differential
geranylgeranylation-dependent Rac1 activation. Cell Death and Diseases (2019) 10:880
https://doi.org/10.1038/s41419-019-2109-9.
124. S.-L. Ryan, S. Beard, M. P. Barr, K. Umezawa, S. Heavey, P. Godwin, S. G. Gray,
D. Cormican, S. P. Finn, K. A. Gately, A. M. Davies, E. W. Thompson, D. J. Richard, K.
J. O’Byrne, M. N. Adams, A.-M. Baird: Targeting NF-κB-mediated inflammatory
pathways in cisplatin-resistant NSCLC. Lung Cancer 135: 217-227, 2019. doi:
10.1016/j.lungcan.2019.07.006.
125. K. Umezawa and Y. Lin: Inhibition of matrix metalloproteinase expression andcellular invasion by NF-κB inhibitors of microbial origin. BBA-Proteins andProteomics 1868(6):140412. doi: 10.1016/j.bbapap.2020.140412.
126. L. Wang, M. Li, Y. Lin, S. Du, Z. Liu, J. Ju, H. Suzuki, M. Sawada and K.
Umezawa: Inhibition of cellular inflammatory mediator production and amelioration oflearning deficit in flies by deep sea Aspergillus-derived cyclopenin. J. Antibiot. 73:
622-629, 2020. DOI: 10.1038/s41429-020-0302-9.
127. C. Saengboonmee, C. Phoomak, S. Supabphol, K. R. Covington, O. Hampton, C.
Wongkham, R. A. Gibbs, K. Umezawa, W. Seubwai, M.-C. Gingras, S. Wongkham:
NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness ofcholangiocarcinoma cells. Life Sciences 262: 118548, 2020,
https://doi.org/10.1016/j.lfs.2020.118548.
128. Y. Ando, Y. Sato, A. Kudo, T. Watanabe, A. Hirakata, A. A. Okada, K. Umezawa
and H. Keino: Anti-inflammatory effects of the NF-κB inhibitor
dehydroxymethylepoxyquinomicin on ARPE-19 cells. Molecular Medicine Reports 22:17

582-590, 2020.
129. Y. Lin, N. Sugiura, J. Ma and K. Umezawa: Cellular anti-inflammatory activity ofnovel I-κB kinase inhibitor ketomycin. In Special Issue “Nonsteroidal
anti-inflammatory drug” Pharmaceutical Science and Biomedical Analysis Journal 3(1):122, 2020.
130. S. Morita, K. Shinoda, T. Yoshida, M. Shimoda, Y. Kanno, R. Mizuno, H. Kono,
H. Asanuma, K. Nakagawa, K. Umezawa, M. Oya: Dehydroxymethylepoxyquinomicin,a novel nuclear factor-κB inhibitor, prevents the development of cyclosporine A
nephrotoxicity in a rat model. BMC Pharmacology and Toxicology (2020) 21:60
https://doi.org/10.1186/s40360-020-00432-3.
131. X. Lu, J. He, Y. Wu, N. Du, X. Li, J. Ju, Z. Hu, K. Umezawa and L. Wang:
Isolation and characterization of anti-inflammatory and antioxidant components fromdeep marine-derived fungus Myrothecium sp. Bzo-1062. Mar. Drugs 2020, 18(12), 597;
https://doi.org/10.3390/md18120597.
132. K. Umezawa, A. Breborowicz, and S. Gantsev: Anticancer activity of novel NF-κB
inhibitor DHMEQ by intraperitoneal administration. Oncology Research 28: 541-550,
2020 doi: https://doi.org/10.3727/096504020X15929100013698.
133. M. F. Candido, G. C. Baldissera, M. Medeiros, K. Umezawa and M. S. Brassesco:
NF-кB inhibition by DHMEQ: in vitro antiproliferative effects on pilocytic astrocytoma
and concise review of the current literature. Child's Nervous System 36: 2675–2684,
2020 https://doi.org/10.1007/s00381-020-04625-3.
134. L. Todorovic, G. Stamenkovic, B. V. Tadic, K. Umezawa, A. Bozovic, S.
Yamashita and B. Stanojevic: Synergistic effect of
17-allylamino-17-demethoxygeldanamycin with dehydroxymethylepoxyquinomicin on
the human anaplastic thyroid carcinoma cell line KTC2. Archives of Biological
Sciences 2020; https://doi.org/10.2298/ABS201010055T.
135. K. Umezawa and K. Shirabe: Direct and indirect anticancer activity ofplant-derived alkaloid conophylline. Critical Reviews in Oncogenesis 26: 67–72, 2021.
DOI: 10.1615/CritRevOncog.2020034129.

18

136. L. Wang and K. Umezawa: Cellular signal transduction and their inhibitors fromdeep-sea organisms. (Review) Marine Drugs 2021, 19, 205. https://doi.org/
10.3390/md19040205.
137. T. Yamanaka, N. Harimoto, T. Yokobori, R. Muranushi, K. Hoshino, K. Hagiwara,
D. Gantumur, T. Handa, N. Ishii, M. Tsukagoshi, T. Igarashi, A. Watanabe, N. Kubo, K.
Araki, K. Umezawa and K. Shirabe: Conophylline inhibits hepatocellular carcinoma by
inhibiting activated cancer-associated fibroblasts through suppression of G protein–coupled receptor 68. Molecular Cancer Therapeutics 20:1019-1028, 2021; DOI:
10.1158/1535-7163.MCT-20-0150
138. Y. Lin, K. Sidthipong, J. Ma, N. Koide, K. Umezawa and T. Kubota: Designed
NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases
drug-sensitivity in mouse plasmacytoma SP2/0 cells. Experimental and Therapeutic
Medicine 22: 1092,2021. DOI: 10.3892/etm.2021.10526
139. J. Ma, Y. Zhang, T. Sugai, T. Kubota, H. Keino, M. El-Salhy, M. Ozaki and K.
Umezawa: Inhibition of cellular and animal inflammatory disease models by NF-κB
inhibitor DHMEQ. Cells 2021,10,2271. https://doi.org/10.3390/cells10092271.
140. H Fujisaki, Y. Nakano, S. Matsuda, K. Suzuki, O. Itano, M. Tanaka, S. Hori, Y.
Abe, H. Yagi, M. Kitago, T. Konno, K. Ishihara, K. Ohno, S. Kishino, K. Umezawa,
and Yuko Kitagawa: Intravenous administration of dehydroxymethylepoxyquinomicin
with polymer enhances the inhibition of pancreatic carcinoma growth in mice.
Anticancer Res. 41: 6003-6012, 2021. doi:10.21873/anticanres.15419.
141. M. Michalak, M. S. Lach, S. Borska, B. Nowakowski, K. Umezawa, W. M.
Suchorska: DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in
ovarian cancer cell lines. Am. J. Cancer Res. 11: 6024-6041, 2021. www.ajcr.us/ISSN:2156-6976/ajcr0086912.
142. K. Ito, A. Okumura, J. S. Takeuchi, K. Watashi, R. Inoue, T. Yamauchi, K.
Sakamoto, Y. Yamashita, Y. Iguchi, M. Une, T. Wakita, K. Umezawa and M. Yoneda:
Dual agonist of farnesoid X receptor and G protein-coupled receptor TGR5 inhibits
hepatitis B virus Infection in vitro and in vivo. Hepatology 74: 83-98, 2021.

19143. K. Umezawa (Editor): Natural Product from the Deep Sea. Book, MDPI, 2022.
144. R. Nakagawa, H. Tateishi, M. O. Radwan, T. Chinen, H. Ciftci, K. Iwamaru, N.
Baba, Y. Tominaga, R. Koga, T. Toma, J. Inoue, K. Umezawa, M. Fujita, and M.
Otsuka: A new 1,2-naphthoquinone derivative with anti-lung cancer activity. Chem.
Pharm. Bull. 70: 477-482, 2022. Doi.org/10.1248/cpb.c21-01087.
145. S. Kojima, M. Hakamata, T. Asanuma, R. Suzuk, J. Tsuruda, T. Nonoyama, Y. Lin,
H. Fukatsu, N. Koide and K. Umezawa: Cellular anti-inflammatory and anti-oxidant
activities of bamboo Sasa albomarginata leaf extract and its constituent coumaric acidmethyl ester. The Scientific World Journal 2022: Article number 8454865.
doi.org/10.1155/2022/8454865
146. Y. Wu, J. Shen, L. Wang, Y. Lin, S. Kojima, S. Okada, K. Umezawa: Isolation of
the anti-inflammatory agent myceliostatin from a methionine-enriched culture of
Myceliophthora thermophila ATCC 42464. J. Nat Prod. February 2023
https://doi.org/10.1021/acs.jnatprod.2c00811
147. M. S. Brassesco, G. M. Roberto, L. E. Delsin, G. C. Baldissera, M. Medeiros, K.
Umezawa, L. G. Tone: A foretaste for pediatric glioblastoma therapy: targeting the
NF-κB pathway with DHMEQ. Child’s Nervous System February 2023,
DOI: 10.1007/s00381-023-05878-4

20